<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oxford Nanopore Technologies Ltd — News on 6ix</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd</link>
<description>Latest news and press releases for Oxford Nanopore Technologies Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 15:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oxford-nanopore-technologies-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e9d578dffbe2df129fa9.webp</url>
<title>Oxford Nanopore Technologies Ltd</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd</link>
</image>
<item>
<title>Block Admission Application</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/block-admission-application-11</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/block-admission-application-11</guid>
<pubDate>Thu, 26 Mar 2026 15:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc has applied for a new block admission of 50,000,000 ordinary shares to the London Stock Exchange, expected to be effective on March 30, 2026. These new shares will rank equally with existing ordinary shares and will be issued under various remuneration plans. This application is in addition to an existing block admission of 40,000,000 ordinary shares, of which 5,160,512 remain available.
Disclaimer*</description>
</item>
<item>
<title>Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/oxford-nanopore-and-adam-innovations-announce-international-collaboration-to-accelerate-advanced-genomic-medicine-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/oxford-nanopore-and-adam-innovations-announce-international-collaboration-to-accelerate-advanced-genomic-medicine-in-japan</guid>
<pubDate>Tue, 17 Mar 2026 10:40:00 GMT</pubDate>
<description>OXFORD, England & TOKYO, March 17, 2026--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.), one of Japan’s leading genetic testing companies, today announce an international collaboration to develop and deploy advanced genomic sequencing and medicine applications based on comprehensive, nanopore sequencing in Japan.</description>
</item>
<item>
<title>Issue of Equity; Director/PDMR Shareholding</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/issue-of-equity-directorpdmr-shareholding-1</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/issue-of-equity-directorpdmr-shareholding-1</guid>
<pubDate>Mon, 09 Mar 2026 16:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced the issuance of 52,182 new ordinary shares on 9 March 2026 to Chief Executive Officer Francis Van Parys, a Person Discharging Managerial Responsibilities, to satisfy vested awards under the Long Term Incentive Plan 2021. These shares were issued at a nil price, with the transaction taking place on the London Stock Exchange.
Disclaimer*</description>
</item>
<item>
<title>Upcoming Investor Events and Conferences</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/upcoming-investor-events-and-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/upcoming-investor-events-and-conferences</guid>
<pubDate>Wed, 04 Mar 2026 07:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced its participation in two upcoming investor conferences in March. The company will attend the Barclays 28th Annual Global Healthcare Conference in Miami on March 11th, featuring an analyst-led fireside chat and investor meetings, with a webcast available. Additionally, Oxford Nanopore will participate in the Berenberg UK Corporate Conference in Hertfordshire on March 17th, also including an analyst-led fireside chat and investor meetings.
</description>
</item>
<item>
<title>Grant of LTIP awards; Director/PDMR Notification</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/grant-of-ltip-awards-directorpdmr-notification</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/grant-of-ltip-awards-directorpdmr-notification</guid>
<pubDate>Tue, 03 Mar 2026 16:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced that on March 3, 2026, Chief Executive Officer Francis Van Parys was granted conditional awards of 583,791 ordinary shares under the Company's Long Term Incentive Plan 2021. These awards, valued based on a share price of £1.2944, are intended to compensate for forfeited incentives from a previous employer and will vest according to their original schedules without a holding period. The transaction occurred outside of a trading venue.
Dis</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/directorpdmr-shareholding-520</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/directorpdmr-shareholding-520</guid>
<pubDate>Tue, 03 Mar 2026 07:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced that Duncan Tatton-Brown, the Chair and a Person Discharging Managerial Responsibilities, purchased 87,000 ordinary shares on 2 March 2026 at a price of £1.1550 per share, totaling £100,485. This transaction was made on the London Stock Exchange and is being disclosed in accordance with the UK Market Abuse Regulation.
Disclaimer*</description>
</item>
<item>
<title>Issue of Equity and Total Voting Rights</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/issue-of-equity-and-total-voting-rights-53</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/issue-of-equity-and-total-voting-rights-53</guid>
<pubDate>Mon, 02 Mar 2026 16:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc has issued 190,389 ordinary shares due to the exercise of options and issuance under remuneration schemes, bringing the total issued share capital to 967,098,047 ordinary shares as of 28 February 2026. The company has no shares in treasury, resulting in a total of 967,098,047 voting rights, which shareholders can use as a denominator for disclosure calculations. A further 5,427,157 ordinary shares remain available under the company's block listing facility.
</description>
</item>
<item>
<title>Annual results for the year ended 31 December 2025</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/annual-results-for-the-year-ended-31-december-2025</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/annual-results-for-the-year-ended-31-december-2025</guid>
<pubDate>Mon, 02 Mar 2026 07:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc reported strong 2025 performance with revenue of £223.9 million, a 22.2% increase on a reported basis, driven by broad-based growth across all regions, products, and customer types, with particular strength in Clinical, BioPharma, and Applied Industrial segments. The company's gross margin improved to 58.6%, and the adjusted EBITDA loss narrowed to £(86.7) million from £(117.9) million in the prior year, reflecting disciplined cost control and increased gross pro</description>
</item>
<item>
<title>Update on legal action against MGI Australia</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/update-on-legal-action-against-mgi-australia</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/update-on-legal-action-against-mgi-australia</guid>
<pubDate>Fri, 27 Feb 2026 15:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc has announced a significant development in its Australian patent proceedings against MGI Australia Pty Ltd., where MGI has conceded that its "Cyclone SEQ WT02" product infringes four of Oxford Nanopore's patents, with liability for infringement not in dispute. A trial is scheduled for 2027 to adjudicate MGI's remaining defenses and consider potential damages. Concurrently, Oxford Nanopore has initiated proceedings in the UK High Court against multiple MGI/BGI ent</description>
</item>
<item>
<title>Director Declaration - John O'Higgins</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/director-declaration-john-ohiggins</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/director-declaration-john-ohiggins</guid>
<pubDate>Fri, 27 Feb 2026 13:30:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced that John O'Higgins, a Non-Executive Director, has been nominated to join the Board of Technip Energies NV as Non-Executive Chair, pending approval at their Annual General Meeting on May 5, 2026. This development is a director declaration under Listing Rule 6.4.9 R(2).
Disclaimer*</description>
</item>
<item>
<title>Share Incentive Plan - Director/PDMR Shareholding</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/share-incentive-plan-directorpdmr-shareholding-1</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/share-incentive-plan-directorpdmr-shareholding-1</guid>
<pubDate>Thu, 12 Feb 2026 16:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc has announced that on February 12, 2026, Nick Keher, the Chief Financial Officer and a Person Discharging Managerial Responsibilities, acquired 105 Partnership Shares at £1.43 per share through the Share Incentive Plan, costing £150.15. Concurrently, the company issued 105 Matching Shares to the Share Incentive Plan trustee on behalf of Mr. Keher, with no associated cost to him. This notification is made in accordance with UK Market Abuse Regulation.
</description>
</item>
<item>
<title>Full Year Trading Update and Notice of Results</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/full-year-trading-update-and-notice-of-results-7</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/full-year-trading-update-and-notice-of-results-7</guid>
<pubDate>Mon, 12 Jan 2026 07:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc anticipates reporting full-year 2025 revenue between £223 million and £224 million, representing approximately 22% growth on a reported basis and 24% at constant currency, slightly exceeding guidance. The company experienced broad-based growth across all geographies and customer end markets, with Clinical revenue up around 60%, BioPharma by 30%, and Applied Industrial by 27%, while Research revenue grew 15%. The PromethION range saw over 40% year-on-year growth. </description>
</item>
<item>
<title>Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/oxford-nanopore-receives-regulatory-approval-063000191</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/oxford-nanopore-receives-regulatory-approval-063000191</guid>
<pubDate>Mon, 12 Jan 2026 06:30:00 GMT</pubDate>
<description>OXFORD, England, January 12, 2026--Oxford Nanopore Technologies today announces that the GridION™ Dx is now both CE and UKCA marked, making it the company’s first IVD device registered in the UK and Europe. The CE and UKCA certification confirms that GridION™ Dx meets stringent international standards for quality, safety, and performance, positioning Oxford Nanopore for future adoption in regulated clinical markets and reflecting its long-term commitment to sequencing-based diagnostics.</description>
</item>
<item>
<title>AGM Post-Meeting Shareholder Engagement Update</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/agm-post-meeting-shareholder-engagement-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/agm-post-meeting-shareholder-engagement-update-1</guid>
<pubDate>Mon, 08 Dec 2025 09:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc has provided an update following its AGM, detailing shareholder engagement regarding Resolution 12. The company has received feedback from major shareholders, which aligns with the Board's focus on maximizing long-term potential and refining strategic planning to prioritize high-priority opportunities. The appointment of Francis Van Parys as Chief Executive Officer is highlighted, bringing experience in scaling life-sciences businesses to lead the commercial stra</description>
</item>
<item>
<title>Appointment of Francis Van Parys as CEO</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/appointment-of-francis-van-parys-as-ceo</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/appointment-of-francis-van-parys-as-ceo</guid>
<pubDate>Mon, 08 Dec 2025 07:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced the appointment of Francis Van Parys as Chief Executive Officer, effective March 2, 2026, succeeding Gordon Sanghera who will transition to an advisory role until early 2027. Van Parys brings over 20 years of experience leading multi-billion-dollar life science businesses, including his current role as President and CEO of Radiometer, and previously held senior positions at Cytiva and GE Healthcare. The company highlighted Van Parys's expertise in scali</description>
</item>
<item>
<title>Upcoming investor conferences</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/upcoming-investor-conferences-1</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/upcoming-investor-conferences-1</guid>
<pubDate>Thu, 27 Nov 2025 07:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced its participation in three upcoming investor conferences in December: the Citi 2025 Global Healthcare Conference on December 2nd, the 37th Annual Piper Sandler Healthcare Conference on December 3rd, and the Berenberg European Conference on December 4th. These events will include analyst-led fireside chats and one-on-one investor meetings, with live webcasts available for the Citi and Piper Sandler events, and replays accessible for at least 30 days.
</description>
</item>
<item>
<title>ONT postpones investor event; reaffirms guidance</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/ont-postpones-investor-event-reaffirms-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/ont-postpones-investor-event-reaffirms-guidance</guid>
<pubDate>Fri, 07 Nov 2025 09:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc announced on 07 November 2025 the postponement of its virtual investor seminar, previously scheduled for 14 November, due to an ongoing CEO succession process. Despite this, the company reaffirmed its financial guidance, expecting full-year 2025 constant currency revenue growth to reach the top end of its 20-23% previously stated range. All other financial metrics are tracking in line with expectations, providing a positive outlook amidst the leadership transitio</description>
</item>
<item>
<title>Upcoming Investor Conferences and Events</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/upcoming-investor-conferences-and-events</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/upcoming-investor-conferences-and-events</guid>
<pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc will host a virtual investor event on November 14, 2025, at 9:00am GMT, focusing on the company's commercial strategy and growth opportunities. Additionally, the company will participate in the J.P. Morgan UK Leaders Conference in London on November 18, 2025, and the Jefferies Global Healthcare Conference in London on November 19, 2025, where they will deliver a presentation at 11:30am GMT. Webcasts and replays of the investor event and conference presentations w</description>
</item>
<item>
<title>Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/bio-techne-and-oxford-nanopore-technologies-expand-agreement-to-accelerate-development-of-genetics-portfolio-through-2032</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/bio-techne-and-oxford-nanopore-technologies-expand-agreement-to-accelerate-development-of-genetics-portfolio-through-2032</guid>
<pubDate>Thu, 09 Oct 2025 11:00:00 GMT</pubDate>
<description>Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced a significant enhancement to its agreement with Oxford Nanopore Technologies (LSE: ONT). The expanded agreement broadens Bio-Techne's ability to develop a portfolio of genetic products on Oxford Nanopore Technologies platforms and extends the collaboration through 2032.</description>
</item>
<item>
<title>Block listing Interim Review</title>
<link>https://6ix.com/company/oxford-nanopore-technologies-ltd/news/block-listing-interim-review-144</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-nanopore-technologies-ltd/news/block-listing-interim-review-144</guid>
<pubDate>Mon, 06 Oct 2025 16:30:00 GMT</pubDate>
<description>Oxford Nanopore Technologies plc reported a block listing six-monthly return on October 6, 2025, for its Share Option Schemes, covering the period from April 6, 2025, to October 5, 2025. The balance of unallotted securities from the previous return was 12,488,383. During this period, the block scheme was not increased. The number of securities issued/allotted under the scheme was 3,980,328, leaving a balance of 8,508,055 securities not yet issued/allotted at the end of the period.
</description>
</item>
</channel>
</rss>